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Abstract Phosphatidylinositol transfer protein (PITP) and 
phospholipase D (PLD) stimulate the formation of constitutive 
secretory vesicles (CSVs) and immature secretory granules 
(ISGs) from the trans-Golgi network (TGN) in a cell-free 
system. The stimulatory effects of PITP and PLD are additive. 
Stimulation by either PITP or PLD is blocked by geneticin, a 
member of the aminoglycoside antibiotics known to bind to 
phosphoinositides. Since the PLD we used is insensitive to 
geneticin, our results suggest that phosphoinositides promote 
secretory vesicle formation as downstream effectors of both 
PITP and PLD, possibly via the recruitment of proteins 
mediating membrane budding and fission. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Inositol phospholipids have emerged as key players in mem-
brane traffic [1-4]. This family of lipids has been shown to 
exert pivotal roles in both the formation of vesicles from 
donor membranes [5,6] and their fusion with acceptor mem-
branes [7-9]. Inositol phospholipids have been implicated in 
membrane trafficking events that constitutively occur in all 
eukaryotic cells [10,11], as well as in those associated with 
the regulated secretion mediated by secretory granules [7-9] 
and synaptic vesicles [12]. Specifically, the machinery operat-
ing in these membrane traffic steps has been shown to include 
several proteins involved in phosphatidylinositol (PI) metab-
olism, including PI transfer proteins (PITPs) [5,7,9,10,13] as 
well as various PI kinases [6,8,11] and phosphoinositide phos-
phatases [12]. 
"Corresponding author. Fax: +49 (6221) 546700. 
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II; TGN, trans-Golgi network 
Another type of phospholipid-modifying enzyme, phospho-
lipase D (PLD), which catalyzes the conversion of phospha-
tidylcholine (PC) to phosphatidic acid (PA), has also been 
implicated in membrane traffic, in constitutive [14,15] and 
regulated [16,17] pathways, and at the level of vesicle forma-
tion [14,15,17] and vesicle fusion [16]. Interestingly, at least 
two levels of interaction between inositol phospholipids and 
PLD have been noted that are potentially relevant for the 
control of membrane traffic [1]. First, mammalian PLD1 re-
quires PI bis phosphate (PIP2) for full activity [18]. Second, 
PA, the product of the PLD reaction, activates type I PI 4-
phosphate 5-kinase, which generates PIP2 [19,20]. Given these 
levels of interaction, it is important to determine whether 
PLD and proteins involved in phosphatidylinositol metabo-
lism indeed cooperate in specific membrane traffic events, and 
if so, how. 
With regard to vesicle fusion, Cockcroft and colleagues [9], 
using a cell-free system, have shown that both PITP and 
ADP-ribosylation factor (ARF), which activates PLD [21], 
stimulate exocytosis. PIP2 was proposed as the common de-
nominator, whose synthesis is increased by both PITP [22] 
and ARF-activated PLD, albeit via distinct mechanisms [9]. 
With regard to vesicle formation, a possible cooperation of 
PITP and PLD has not been studied. To investigate this issue, 
we have exploited the observations that the formation of im-
mature secretory granules (ISGs) from the trans-Golgi net-
work (TGN) is promoted by both PITP [5] and PLD [17]. 
The latter is thought to be a downstream effector in the stim-
ulation of ISG formation by ADP-ribosylation factor (ARF) 
[23-25]. Using a cell-free system that reconstitutes the forma-
tion of ISGs and constitutive secretory vesicles (CSVs) from 
the TGN [26], we here investigate whether PITP and PLD 
cooperate in secretory vesicle formation from the TGN. Fur-
thermore, by using aminoglycoside antibiotics, which bind to 
PIP2 [27,28], and an aminoglycoside-insensitive PLD as tools, 
we examine whether phosphoinositides are a possible common 
denominator in the stimulation of secretory vesicle formation 
by both PITP and PLD. 
2. Materials and methods 
2.1. Materials 
Recombinant mouse PITP (a isoform) was prepared from inclu-
sion bodies after expression of the cDNA in Escherichia coli [29]. 
Phospholipase D purified from Streptomyces chromofuscus [30] was 
purchased from Sigma. Analysis of the commercial PLD preparation 
by SDS-PAGE followed by Coomassie Blue staining confirmed the 
high degree of purity (> 90%) of the PLD (data not shown). 1-Pal-
mitoyl-2-[6-[(7-nitro-2-l,3-benzoxadiazol-4-yl)amino]caproyl]-sn-glyc-
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ero-3-phosphocholine (C6-NBD-PC) and l-palmitoyl-2-[6-[(7-nitro-2-
l,3-benzoxadiazol-4-yl)amino]caproyl]-sn-glycero-3-phosphate (Cß-
NBD-PA) were obtained from Avanti Polar Lipids. Geneticin was 
obtained from Gibco BRL. 
2.2. Cell-free secretory vesicle formation 
Cell-free formation of secretory vesicles from the TGN in a PC12 
cell post-nuclear supernatant (PNS, 2 mg/ml protein), separation of 
post-TGN secretory vesicles from the TGN by differential centrifuga-
tion, and quantification of the formation of CSVs and ISGs using 
[35S]sulphate-labelled heparan sulfate proteoglycan (hsPG) and secre-
togranin II (Sgll) as markers, respectively, were performed, using a 
previously established system [26,31,32], as described in Fig. 1 of [5], 
except that vesicle formation is expressed as a percentage of labelled 
marker in the PNS (rather than PI fraction [32]) kept at 4°C. The 
reaction volume was 150 ill. When indicated, recombinant mouse 
PITPa, S. chromofuscus PLD and geneticin were added to the reac-
tion mixture on ice before warming to 37°C, as follows. Recombinant 
mouse PITPa was added from a stock containing 333 ug/ml recombi-
nant protein and 0.3-0.6 ug/ml BSA which was dialyzed against HBS 
[31] (0.25 M sucrose, 1 mM EDTA, 1 mM magnesium acetate, 1.6 
mM Na2S04 , 10 mM HEPES-KOH, pH 7.2) prior to use; controls 
received the equivalent volume of a stock containing 0.3-0.6 |xg/ml 
BSA only, also dialysed against HBS. PLD was added from a stock in 
HBS containing either 50 or 100 U/|il according to the manufacturer's 
specification (one unit of PLD activity corresponds to 1.0 umole of 
choline liberated from L-a-phosphatidylcholine (egg yolk) per hour at 
pH 8.0 at 30°C). Geneticin was added from a neutralized 0.1 M stock 
in HBS. After setting up the reaction mixtures, aliquots of 50 ill were 
removed for the determination of PLD activity as described below, 
and the remaining 100 (il were subjected to cell-free secretory vesicle 
formation (1 h, 37°C). The data shown are the mean of either four 
determinations (duplicate cell-free reactions using two independently 
prepared PNSs) or six determinations (either triplicate cell-free reac-
tions using two independently prepared PNSs, or duplicate cell-free 
reactions using three independently prepared PNSs). The mean of the 
duplicate or triplicate control reactions was calculated and set to 
100%, and the other values of vesicle formation obtained with a given 
PNS were expressed relative to this control. The efficiency of vesicle 
formation in the control condition was usually between 10% and 15%, 
i.e. 10-15% of the labelled markers were transferred from the TGN to 
post-TGN secretory vesicles in the cell-free reactions. 
2.3. Determination of PLD activity 
PLD activity was determined by quantifying the conversion of C$-
NBD-PC to Q-NBD-PA, using a modification of the method de-
scribed by Liscovitch and colleagues [18,33]. For each set of PLD 
assays, an aliquot (464 (xl) of C6-NBD-PC was removed from a 
1 mg/ml stock in chloroform, dried under a stream of nitrogen, and 
dissolved in HBS with the aid of sonication for 5 min at room temper-
ature. Aliquots (<10 ill) of the C6-NBD-PC in HBS were added to the 
50 JJ.1 aliquots of the reaction mixtures of cell-free vesicle formation 
(see above) to give a final concentration of 0.25-0.3 mM Q-NBD-PC. 
After incubation for 15 min at 37°C (or 4°C for the determination of 
background), reactions were terminated by the addition of 900 jo.1 
chloroform/methanol/9 N HC1 (1:1:0.006, v/v). Following addition 
of 450 JJ.1 water and phase separation by brief centrifugation, the 
chloroform phase was collected and dried in a SpeedVac. The residue 
was dissolved in 20 |il chloroform/methanol (1:1, v/v) and spotted on 
silica gel 60 TLC plates (Merck). The TLC plates were developed in a 
solvent mixture containing 2-propanol/ethylacetate/chloroform/meth-
anol/water (50:50:50:21:18, v/v). TLC plates were transilluminated 
with UV light (wavelength 312 nm) and the fluorescence was recorded 
by video imaging. The fluorescence intensity of the C6-NBD-PA-con-
taining bands was quantified using the MacBas 2.3.1 programme. The 
signal-to-noise ratio (incubation in the absence of exogenous PLD at 
37°C vs. 4°C) was at least 5:1. The data shown are the mean of six 
determinations (triplicate cell-free reactions using two independently 
prepared PNSs). For any given PNS, the mean of the triplicate sam-
ples kept at 4°C was calculated and subtracted from the values ob-
tained after incubation at 37°C. The mean of the resulting values for 
the triplicate incubation at 37°C in the control condition was calcu-
lated, set to 100%, and the other values of C6-NBD-PA production at 
37°C obtained with a given PNS were expressed relative to this con-
trol. 
3. Results and discussion 
3.1. The aminoglycoside geneticin blocks the PITP-induced 
stimulation of secretory vesicle formation from the TGN 
Aminoglycoside antibiotics such as neomycin have been 
shown to bind to phosphoinositides, in particular PIP2 
[27,28]. To investigate whether the stimulation of secretory 
vesicle formation from the T G N observed upon addition of 
PITP [5] involved phosphoinositides, we examined the effect 
of geneticin, an aminoglycoside related to neomycin, in a pre-
viously established cell-free system [26,32] that reconstitutes 
the formation of CSVs and ISGs (collectively referred to as 
pos t -TGN secretory vesicles) from the T G N . As shown in Fig. 
1, 1 m M geneticin completely blocked the stimulation of CSV 
(hsPG marker, Fig. 1, top) and ISG (Sgll marker, Fig. 1, 
bot tom) formation observed upon addition of 300 n M re-
combinant mouse P I T P a , resulting in values below the con-
trol. The aminoglycoside also partially inhibited the basal 
CSV formation observed in the absence of exogenous P ITP 
and marginally inhibited basal ISG formation (Fig. 1). The 
extent of this inhibition varied between different P N S prepa-
rations (compare Fig. 3A). Significant ( ~ 2 5 % ) inhibition of 
vesicle formation was already observed in the presence of 200 
| iM geneticin (data not shown). 
3.2. Exogenous PLD stimulates secretory vesicle formation 
from the TGN 
P L D is thought to provide an alternative route to P ITP to 
increase phosphoinositide levels [9] because PA, the product 
of the P L D reaction, stimulates type I PI 4-phosphate 5-kin-
ase [20]. To explore this issue with regard to pos t -TGN secre-
tory vesicle formation, we first investigated whether P L D 
stimulates the formation of CSVs and ISGs from the T G N 
Control PITP Geneticin PITP + 
Geneticin 
Fig. 1. Geneticin blocks the stimulation of secretory vesicle forma-
tion by PITPa. Cell-free secretory vesicle formation was performed 
in the absence (Control) and presence of 300 nM recombinant 
mouse PITPa (PITP), 1 mM geneticin (Geneticin) and 300 nM re-
combinant mouse PITPa plus 1 mM geneticin (PITP+Geneticin). 
The formation of CSVs (hsPG, top) and ISGs (Sgll, bottom) was 
determined as described in Section 2 and is expressed as a percent-
age of the control, which was set to 100%. Data are the mean of 
four determinations; bars indicate the standard deviation. 
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in our cell-free system, as has been shown by Shields and 
colleagues [17] for ISGs in another cell-free system. For the 
purpose of our study, it was important to use a PLD whose 
activity does not depend on PIP2 and is unaffected by genet-
icin. We therefore chose highly purified PLD from S. chromo-
fuscus [30], rather than the recombinant human PLD1 previ-
ously used for cell-free ISG formation [17], as a tool to study 
the effect of PA production on post-TGN secretory vesicle 
formation. Fig. 2A shows that addition of S. chromofuscus 
PLD resulted in a concentration-dependent increase in PA 
production under the conditions of cell-free secretory vesicle 
formation. Addition of the bacterial PLD to the cell-free sys-
tem indeed caused a stimulation of the formation of CSVs 
and ISGs which approached a plateau at 1 U/ul PLD (Fig. 
2B). This stimulation was abolished by pretreatment of the 
PLD preparation with proteinase K (data not shown), elimi-
nating the possibility that it was due to a non-proteinaceous 
component in the PLD preparation. Interference with the 
PLD-catalyzed production of PA by transphosphatidylation, 
which occurs in the presence of primary, but not secondary, 
alcohols [17,34], gave inconclusive results because both pri-
mary and secondary alcohols (propanol, butanol; 1% final 
concentration) caused an apparently unspecific inhibition of 
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Fig. 2. Exogenous PLD stimulates secretory vesicle formation. PNS 
was incubated under the conditions of cell-free secretory vesicle for-
mation in the presence of the indicated concentrations of PLD from 
5. chromofuscus. A: Aliquots of the PNS were analyzed for PLD 
activity as described in Section 2. B: Aliquots of the PNS were ana-
lyzed for the formation of CSVs (hsPG, open circles) and ISGs 
(Sgll, filled circles) as described in Section 2. A, B: PLD activity 
and secretory vesicle formation are expressed as a percentage of the 
values obtained in the absence of added PLD, which were set to 
100%. Data are the mean of six (1 U/ul, nine) determinations; bars 
indicate the standard deviation. 
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Fig. 3. Geneticin blocks the stimulation of secretory vesicle forma-
tion by exogenous PLD without affecting its activity. PNS was incu-
bated under the conditions of cell-free secretory vesicle formation in 
the absence (Control) and presence of 1 U/ul S. chromofuscus PLD 
(PLD), 1 mM geneticin (Geneticin) and 1 U/ul S. chromofuscus 
PLD plus 1 mM geneticin (PLD+Geneticin). A: Aliquots of the 
PNS were analyzed for the formation of CSVs (hsPG, top) and 
ISGs (Sgll, bottom) as described in Section 2. Vesicle formation is 
expressed as a percentage of the control, which was set to 100%. 
Data are the mean of six determinations; bars indicate the standard 
deviation. B: Aliquots of the PNS were analyzed for PLD activity 
as described in Section 2. The thin-layer chromatogram of triplicate 
reactions is shown. PC, Q-NBD-PC standard (arrowheads); PA, 
Cg-NBD-PA standard (arrows); 4°C, incubation as in the control 
condition except that 4°C rather than 37°C was used. 
secretory vesicle formation in our cell-free system (data not 
shown). 
3.3. Geneticin blocks the stimulation of secretory vesicle 
formation by exogenous PLD without inhibiting its activity 
If the stimulation of post-TGN secretory vesicle formation 
by exogenous PLD involved a PA-mediated increase in phos-
phoinositide levels, one would expect this stimulation to be 
sensitive to aminoglycosides. Indeed, as shown in Fig. 3A, 
addition of 1 mM geneticin to the cell-free system completely 
blocked the stimulation of both CSV and ISG formation ob-
served in the presence of 1 U/ul S. chromofuscus PLD. Im-
portantly, geneticin did not inhibit the PLD-catalyzed increase 
in PA levels (Fig. 3B). We conclude that the PLD-induced 
increase in PA levels in turn leads to an increase in an effector 
of secretory vesicle formation that is sensitive to aminoglyco-
sides, such as PIP2. 
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Fig. 4. Additive stimulatory effects of PITPa and PLD on secretory 
vesicle formation. Cell-free secretory vesicle formation was per-
formed in the absence (Control) and presence of 300 nM recombi-
nant mouse PITPa (PITP), 1 U/ul S. chromofuscus PLD (PLD) and 
300 nM recombinant mouse PITPa plus 1 U/|xl S. chromofuscus 
PLD (PITP+PLD). The formation of CSVs (hsPG, top) and ISGs 
(Sgll, bottom) was determined as described in Section 2 and is ex-
pressed as a percentage of the control, which was set to 100%. Data 
are the mean of six determinations; bars indicate the standard devi-
ation. Vesicle formation in the presence of both PITPa and PLD is 
significantly different from that in the presence of either PITPa or 
PLD alone (Student's i-test, P < 0.005). 
3.4. PITP and PLD cooperate in promoting secretory vesicle 
formation from the TGN 
The blockade by geneticin of both the PITP-induced and 
the PLD-induced stimulation of secretory vesicle formation 
from the TGN is consistent with a central role of PIP2 in 
these membrane traffic events. If, in analogy to the stimula-
tion of exocytosis [9], the stimulation of secretory vesicle for-
mation by PITP and that by PLD reflect two distinct mech-
anisms of increasing the level of PIP2, PITP and PLD should 
exert additive stimulatory effects on vesicle formation. Indeed, 
the combined addition of 300 nM recombinant mouse PITPa 
and 1 U S. chromofuscus PLD per ¡of to the cell-free system 
resulted in a significantly greater stimulation of post-TGN 
secretory vesicle formation than that observed with either 
protein alone (Fig. 4). 
3.5. Conclusions 
We provide evidence for cooperativity between PITP and 
PLD in secretory vesicle formation from the TGN. With re-
gard to PLD, our data confirm the conclusion by Shields and 
colleagues [17] that PLD stimulates ISG formation and extend 
this notion to the other class of secretory vesicles formed in 
the TGN, the CSVs. Our observation that the aminoglycoside 
geneticin blocks both the stimulation of secretory vesicle for-
mation by PITP and that by PLD (but not the PLD activity 
itself) suggests that phosphoinositides, known targets of ami-
noglycosides, are downstream effectors in both pathways of 
stimulation. The inhibition of PITP-stimulated and PLD-
stimulated secretory vesicle formation by geneticin is unlikely 
to reflect interference with the coatomer machinery [35,36] 
because (i) secretory vesicle formation from the TGN does 
not involve coatomer [24] and (ii) geneticin neither precipi-
tates coatomer (in contrast to neomycin) nor inhibits its bind-
ing to Golgi membranes at the concentrations used here [37]. 
It is also highly improbable that the inhibition of PITP-stimu-
lated and PLD-stimulated secretory vesicle formation by ge-
neticin is due to binding of ATP, which has been reported for 
the related aminoglycoside neomycin [38]. ATP is required not 
only for PITP-stimulated and PLD-stimulated, but also basal 
post-TGN secretory vesicle formation [26], which still oc-
curred in the presence of geneticin. 
The observation that at least half of the basal post-TGN 
secretory vesicle formation was not inhibited by geneticin does 
not necessarily imply a lack of involvement of phosphoinosi-
tides in basal vesicle formation. In our cell-free system, about 
half of the post-TGN secretory vesicle formation seen under 
control conditions is refractory to inhibition by brefeldin A, 
which completely blocks the formation of these vesicles in 
intact cells [39], and such refractoriness may also apply to 
inhibition by geneticin. 
In conclusion, phosphoinositides are pivotal components of 
the machinery mediating post-TGN secretory vesicle forma-
tion. Given that phosphoinositides promote the membrane 
binding of numerous cytoplasmic proteins including compo-
nents of the cytoskeleton [3,4], an attractive, though not ex-
clusive, function of phosphoinositides may lie in the recruit-
ment to the TGN membrane of proteins mediating vesicle 
budding and fission. 
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